Sydney, Australia: The daily administration of cannabis extracts from plants is well tolerated and improves the general quality of life of patients with glioma (brain cancer), according to clinical study data published in the journal Frontiers in Oncology.
A team of Australian researchers studied the daily administration of cannabis extracts containing either a 1 to 1 ratio of THC and CBD or a 4 to 1 ratio of THC and CBD to 83 patients with glioma. The subjects in the study consumed the extracts over a period of at least four weeks.
Investigators reported that the subjects reacted most positively to extracts containing equal ratios of THC and CBD.
They concluded, “This study provides robust evidence that medicinal cannabis administered to this patient population is safe, well tolerated and can provide symptomatic relief for these patients. … [It] Points out that cannabis, especially a 1: 1 CBD / THC mixture, can help with many symptoms that affect quality of life [quality of life] in this patient population, especially sleep disorders. As such an MC [medical cannabis] can be a valuable potential therapy for maintaining the best quality of life and daily function for this population with a poor prognosis, [while] also support patients with cancer therapies and potentially life-prolonging therapies. “
The full text of the study, “A Phase II Randomized Clinical Trial to Evaluate the Tolerance of Two Different Ratios of Medical Cannabis in Patients with High-Grade Gliomas,” appears in Frontiers in Oncology. Additional information on cannabinoids and gliomas is available from NORML.